Racura Oncology Ltd
RAC.AX·ASX·Healthcare
1.4800+0.0800 (+5.71%)today
At close: Nov 5, 4:10 PM AEDT · May be delayed up to 20 min · AUD
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close1.4000
Open1.4100
Day range1.40001.4950
52-week range1.40003.7900
Off day high−1.00%
Off 52-week high−60.95%
Volume157.14K
Avg. volume (3M)78.93K
Market cap290.18M
EPS (TTM)-0.0600
Forward P/E-14.37
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.96
Shares outstanding196.07M
Short interest—
Earnings dateJul 20, 2025 (est.)
Analyst target—
Profit margin0.00%
Against its peers
Compare in full ›| RAC.AX | BBOT | PBYI | CBIO | PTX.AX | RLMD | |
|---|---|---|---|---|---|---|
| Market cap | 290.18M | 184.40M | 551.82M | 513.37M | 60.62M | 444.81M |
| P/E (TTM) | — | — | 21.0 | — | — | — |
| Forward P/E | -14.4 | -0.8 | 30.5 | -5.3 | 5.3 | -10.2 |
| Price/book | 8.0 | 0.6 | 3.9 | 2.9 | 3.8 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −54.84% | −81.29% | +106.46% | +5.07% | +10.87% | +70.12% |
| Today | +5.71% | −0.86% | +4.60% | +5.82% | +3.92% | −2.34% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All RAC.AX news ›Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer
Oct 12, 2026, 07:00 ET The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and has recommended the trial proceed…
Racura Oncology Advances to New RC220 Dose Level in Harness-1 Lung Cancer Trial
Racura Oncology can escalate RC220 to 100mg/sqm in its lung cancer trial after no safety concerns emerged at the initial dose. Racura Oncology (ASX: RAC) has received safety review committee (SRC) clearance for lead candidate RC220…
From the 4Search news index, newest first.